Multiple melanoma-associated antigens (presented in vaccinia melanoma cell lysate) (VMCL)

Multiple melanoma-associated antigens presented in vaccinia melanoma cell lysate (VMCL) represent a polyvalent approach to cancer immunotherapy, specifically targeting malignant melanoma. This complex target consists of a diverse array of proteins derived from human melanoma cell lines (typically SK-MEL-13 and MS-24) that have been lysed following infection with the vaccinia virus (NCI Drug Dictionary). The resulting lysate contains well-characterized antigens such as MAGE-1, MAGE-3, MART-1, gp100, and tyrosinase, which are frequently overexpressed in melanoma cells but have limited expression in normal tissues (Sondak et al., 2002). When administered as a vaccine, these antigens are processed by antigen-presenting cells to prime the immune system, particularly CD8+ cytotoxic T cells, to recognize and destroy melanoma cells throughout the body. Clinical studies have indicated that the therapeutic efficacy of these antigens may be influenced by the patient's human leukocyte antigen (HLA) profile, with specific genotypes like HLA-A2 and HLA-C3 showing improved survival outcomes in trials involving the Melacine vaccine (Mitchell et al., 2002).

Other names

MelacineVaccinia melanoma cell lysateVMCLPolyvalent melanoma vaccine antigensMelanoma-associated antigens

The mechanism involves active specific immunotherapy where the vaccinia melanoma cell lysate (VMCL) provides a broad spectrum of melanoma-associated antigens (MAAs) to the host's immune system. These antigens are captured by professional antigen-presenting cells (APCs), processed, and presented via MHC molecules to T-lymphocytes. This process induces a polyvalent immune response, including the activation of CD8+ cytotoxic T-lymphocytes (CTLs) and B-cells specific to melanoma markers such as MAGE and tyrosinase (Mitchell et al., 1988; Sondak et al., 2002).